Welcome to our dedicated page for Vogenx SEC filings (Ticker: VOGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Vogenx's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Vogenx's regulatory disclosures and financial reporting.
Vogenx, Inc. (VOGX), a clinical-stage biopharmaceutical company focused on serious metabolic and gastrointestinal diseases, has appointed Ken Toombs to its Board as a Class II independent director, effective September 21, 2026, with a term running until the 2028 annual meeting of stockholders. He will serve on the Audit, Compensation, and Nominating and Corporate Governance Committees and act as Chair of the Audit Committee. The Board also named Peter Pieraccini as Chair of the Compensation Committee. Toombs brings roughly three decades of global professional services and life sciences-related leadership, including roles as Chief Executive Officer of PA Consulting and senior positions at Infosys Consulting, Capgemini Consulting, PricewaterhouseCoopers and IBM. Vogenx is developing its lead candidate, mizagliflozin, an investigational SGLT1 inhibitor, for post-bariatric hypoglycemia, gastroparesis and GIP-dependent Cushing’s Syndrome, supported by clinical data from more than 500 subjects across 10 studies.
Vogenx, Inc. (VOGX), a clinical-stage biotech focused on mizagliflozin for serious metabolic and gastrointestinal diseases, reported a larger net loss and a significant cash burn for the quarter and six months ended June 30, 2026. Net loss was $384,430 for the quarter and $859,882 for six months, up from $294,797 and $651,416 a year earlier, driven by higher research and development and general and administrative expenses.
At June 30, 2026, Vogenx had $193,017 of cash and cash equivalents, $3.19 million in total liabilities and a stockholders’ deficit of $1.78 million, with an accumulated deficit of $11.7 million. However, in August 2026 the company completed its IPO, issuing 7,187,500 shares at $13.00 per share and receiving approximately $84.9 million in net proceeds, plus automatic conversion of preferred stock, convertible notes and warrants into common stock. Management now believes available cash, including IPO proceeds, will fund operations for at least 12 months and expects funding through 2028, though substantial additional capital will be needed before any Phase 3 trials. A one-for-three reverse stock split became effective July 28, 2026, and disclosure controls were deemed ineffective due to previously identified material weaknesses in internal control over financial reporting.
Vogenx, Inc. (VOGX) reports that Janus Henderson Group Ltd. has filed a Schedule 13G stating beneficial ownership of 1,923,076 shares of Vogenx common stock, representing 13.0% of the class, held through various affiliated investment advisers acting as asset managers for client accounts.
The Janus Henderson asset managers have shared power to vote and to dispose of all 1,923,076 shares, with no sole voting or dispositive power. The filing states that these asset managers may be deemed beneficial owners due to investment and voting discretion, while the client managed portfolios retain the rights to all dividends and sale proceeds.
Vogenx, Inc. (VOGX) reports that JonesTrading Institutional Services LLC fully exercised its 45‑day over‑allotment option related to Vogenx’s recent initial public offering. The option covered 937,500 additional shares of common stock at a public offering price of $13.00 per share, closing on August 19, 2026 and generating additional gross proceeds of approximately $12,187,500 before underwriting discounts, commissions and expenses. Including these shares, a total of 7,187,500 shares have been issued and sold in the offering, for aggregate gross proceeds of approximately $93,437,500.
Vogenx, Inc. (VOGX) reported initial insider ownership for director and Chief Scientific Officer Dr. William Wilkison and affiliated entity WOWIG, LLC. Dr. Wilkison holds stock options to acquire up to 116,666 shares of common stock at an exercise price of $1.03 per share, fully vested and exercisable, expiring on July 27, 2027. He also holds options covering 26,666 shares at an exercise price of $1.26 per share, vesting in three annual tranches from April 1, 2026 through April 1, 2028, expiring on January 1, 2031. In addition, 1,800,000 shares of common stock are held indirectly through WOWIG, LLC, of which Dr. Wilkison is the sole member and which is the direct owner of those securities.
Vogenx, Inc. (symbol VOGX) reports the initial holdings of director Boris Timothy on a Form 3. He holds several stock options to acquire common stock directly, with exercise prices between $0.93 and $1.20 per share and expirations from 2032 through 2036.
Two option positions at a $0.93 exercise price cover 8,333 and 3,333 underlying shares; the 8,333-share grant is fully vested and exercisable as of the reporting date. Three additional grants at exercise prices of $1.20 and $1.14 cover 3,333, 3,333, and 8,333 underlying shares, with shares vesting in roughly equal annual installments from 2025 through 2028, subject to his continued service.
Vogenx, Inc. (VOGX) reported the initial beneficial ownership of director and Chief Financial Officer Steven R. Delmar on a Form 3. He directly owns 700,000 shares of Common Stock. He also holds stock options to acquire 83,333 shares at an exercise price of $0.93 per share, fully vested and exercisable, expiring on July 27, 2032.
Delmar additionally holds options to acquire 25,000 shares at $1.14 per share, vesting in three annual tranches from April 1, 2026 through April 1, 2028, and expiring on January 1, 2036. He also holds a Convertible Promissory Note convertible into 4,273 shares of Common Stock at $11.70 per share, with automatic conversion immediately prior to the company’s IPO and stated maturity on the earlier of March 8, 2027 or a Company Sale.
Vogenx, Inc. (VOGX) director Richard M. Gorman reported his beneficial ownership of stock options in an initial insider filing. He lists five Stock Option (right to buy) positions over Vogenx common stock with exercise prices of $0.93, $1.14, and $1.20 per share, expiring between 2032 and 2036. Some options covering 8,333 underlying shares at $0.93 and $1.14 are fully vested and exercisable, while others over 3,333 underlying shares at $1.20 vest in three equal annual installments on specified dates, subject to his continued service.
Vogenx, Inc. (VOGX) reports initial beneficial ownership on a Form 3 for three reporting persons: Richard Bentley Cheatham, Lynn Anne Cheatham, and Stanhope-1, LLC, each identified as a ten percent owner. Stanhope-1, LLC holds 700,000 shares of Common Stock indirectly for the Cheathams, who as managers share voting and dispositive power over these securities.
Dr. Richard Cheatham also holds stock options directly. One option covers 50,000 shares of Common Stock at an exercise price of $0.93 per share and is fully vested and exercisable. A second option covers 21,666 shares at an exercise price of $1.14 per share, vesting in three equal installments of 7,222 shares on April 1, 2026, 2027, and 2028, subject to his continued service.
Vogenx, Inc. (VOGX) director Peter Pieraccini filed an initial ownership report showing derivative positions in the company. He holds stock options directly for 8,333 shares of common stock at $0.93 expiring July 27, 2032, 3,333 shares at $0.93 expiring January 25, 2033, 3,333 shares at $1.20 expiring January 27, 2034, 3,333 shares at $1.20 expiring January 27, 2035, and 8,333 shares at $1.14 expiring January 1, 2036. He also indirectly holds a Convertible Promissory Note through Steel Buddha, LLC, convertible into 42,735 shares of common stock at $11.70 per share, with automatic conversion immediately prior to Vogenx’s initial public offering and maturity on the earlier of March 8, 2027 or a Company Sale.